Standard BioTools Inc. (LAB) Gross Margin
- Gross margin · 12 months: Value 50.49%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 50.49% | Gross profit / revenue. Period ending 2026-06-30. $42.71M ÷ $84.60M × 100 ≈ 50.49% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 42.71M USD | Gross Profit |
| Revenue | 84.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 41.89M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $42.71M | $84.60M | $41.89M | 50.49% |
| 2026-03-31 | $42.80M | $86.25M | $43.45M | 49.62% |
| 2025-12-31 | $42.54M | $85.33M | $42.79M | 49.86% |
| 2025-09-30 | $81.90M | $169.74M | $87.84M | 48.25% |
| 2025-06-30 | $84.54M | $172.27M | $87.73M | 49.07% |
| 2025-03-31 | $79.81M | $169.69M | $89.87M | 47.04% |
| 2024-12-31 | $84.26M | $174.43M | $90.17M | 48.31% |
| 2024-09-30 | $75.71M | $155.90M | $80.19M | 48.57% |
| 2024-06-30 | $63.66M | $136.30M | $72.64M | 46.71% |
| 2024-03-31 | $62.36M | $126.76M | $64.40M | 49.19% |
| 2023-12-31 | $50.45M | $106.34M | $55.89M | 47.44% |
| 2023-09-30 | (m) | $105.17M | (m) | (m) |
| 2023-06-30 | (m) | $105.45M | (m) | (m) |
| 2023-03-31 | (m) | $96.56M | (m) | (m) |
| 2022-12-31 | (m) | $97.95M | (m) | (m) |
| 2022-09-30 | (m) | $109.19M | (m) | (m) |
| 2022-06-30 | (m) | $112.05M | (m) | (m) |
| 2022-03-31 | (m) | $124.29M | (m) | (m) |
| 2021-12-31 | (m) | $130.58M | (m) | (m) |
| 2021-09-30 | (m) | $136.92M | (m) | (m) |
| 2021-06-30 | (m) | $148.28M | (m) | (m) |
| 2021-03-31 | (m) | $143.32M | (m) | (m) |
| 2020-12-31 | $67.70M | $138.14M | (m) | 49.01% |
| 2020-09-30 | (m) | $125.98M | (m) | (m) |
| 2020-06-30 | (m) | $112.61M | (m) | (m) |
| 2020-03-31 | (m) | $114.75M | (m) | (m) |
| 2019-12-31 | $64.28M | $117.24M | $52.96M | 54.83% |
| 2019-09-30 | $65.20M | $117.13M | $51.93M | 55.67% |
| 2019-06-30 | $66.99M | $119.59M | $52.61M | 56.01% |
| 2019-03-31 | $65.21M | $117.83M | $52.62M | 55.34% |
| 2018-12-31 | $61.65M | $112.96M | $51.31M | 54.57% |
| 2018-09-30 | (m) | $108.38M | (m) | (m) |
| 2018-06-30 | (m) | $104.17M | (m) | (m) |
| 2018-03-31 | (m) | $101.65M | (m) | (m) |
| 2017-12-31 | (m) | $101.94M | (m) | (m) |
| 2017-09-30 | (m) | $99.28M | (m) | (m) |
| 2017-06-30 | (m) | $96.72M | (m) | (m) |
| 2017-03-31 | (m) | $100.98M | (m) | (m) |
| 2016-12-31 | (m) | $104.45M | (m) | (m) |
| 2016-09-30 | (m) | $110.08M | (m) | (m) |
| 2016-06-30 | (m) | $116.54M | (m) | (m) |
| 2016-03-31 | (m) | $116.99M | (m) | (m) |
| 2015-12-31 | (m) | $114.71M | (m) | (m) |
| 2015-09-30 | (m) | $117.48M | (m) | (m) |
| 2015-06-30 | (m) | $118.47M | (m) | (m) |
| 2015-03-31 | (m) | $117.46M | (m) | (m) |
| 2014-12-31 | (m) | $116.46M | (m) | (m) |
| 2014-09-30 | (m) | $103.85M | (m) | (m) |
| 2014-06-30 | (m) | $92.50M | (m) | (m) |
| 2014-03-31 | (m) | $82.37M | (m) | (m) |
| 2013-12-31 | (m) | $71.18M | (m) | (m) |
| 2013-09-30 | (m) | $65.96M | (m) | (m) |
| 2013-06-30 | (m) | $60.46M | (m) | (m) |
| 2013-03-31 | (m) | $55.92M | (m) | (m) |
| 2012-12-31 | (m) | $52.33M | (m) | (m) |
| 2012-09-30 | (m) | $49.67M | (m) | (m) |
| 2012-06-30 | (m) | $47.48M | (m) | (m) |
| 2012-03-31 | (m) | $45.11M | (m) | (m) |
| 2011-12-31 | (m) | $42.87M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $33.56M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $25.41M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |